The acquisition of Pelican completed
The earlier announced acquisition of a majority stake of Spitalul Pelican is now completed as all necessary approvals have been granted. The cash flow impact of the acquisition is projected at EUR 23 million, including purchasing price, debt, transfer of certain assets and investments into operations. Spitalul Pelican will be consolidated from mid-September 2018. Revenue for 2017 was EUR 15 million with an EBITDA of EUR 3.7 million. For further information, please contact: Paula Treutiger, Corporate Communication and Investor Relations Director +46 733 666 599 paula.treutiger@